Role of T-lymphocytes and pro-inflammatory mediators in the pathogenesis of chronic obstructive pulmonary disease

International Journal of COPD

Volumn 3, Issue 4, 2008, Pages 531-541

  Gadgil, Aneal ^a   Duncan, Steven R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Adaptive immunity; COPD; Cytokines; T lymphocytes

Indexed keywords

AUTOANTIGEN; BACTERIAL ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIGEN;

ADAPTIVE IMMUNITY; ANTIGEN ANTIBODY REACTION; ANTIGENICITY; AUTOIMMUNITY; B LYMPHOCYTE; BACTERIAL INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; INFLAMMATORY INFILTRATE; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOPOIESIS; MEDIATOR; MEDIATOR RELEASE; PATHOPHYSIOLOGY; RECURRENT INFECTION; RESPIRATORY EPITHELIUM; REVIEW; SMOKING; T LYMPHOCYTE; VIRUS INFECTION;

ANIMALS; ANTIGENS; ANTIMICROBIAL CATIONIC PEPTIDES; AUTOANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; ELASTIN; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKINS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 60249085440     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Aaron SD, Angel JB, Lunau M, et al. 2001. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 163:349-55.
2. Adlowitz DG, Kirkham C, Sethi S, et al. 2006. Human serum and mucosal antibody responses to outer membrane protein G1b of Moraxella catarrhalis in chronic obstructive pulmonary disease. FEMS Immunol Med Microbiol, 46:139-46.
3. Amadori A, Zamarchi R, De Silvestro G, et al. 1995. Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med, 1:1279-83.
4. Banerjee D, Khair OA, Honeybourne D. 2004. Impact of sputum bacteria on airway inflammation and health status in clinically stable COPD. Eur Respir J, 23:685-91.
5. Barcelo B, Pons J, Fuster A, et al. 2006. Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease. Clin Exp Immunol, 145:474-9.
6. Barczyk A, Pierzchaia W, Kon OM, et al. Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease. J Allergy Clin Immunol, 117:1484-92.
7. Beeh KM, Kornmann O, Buhl R, et al. 2003. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin-8 and leukotriene B4. Chest, 123:1240-7.
8. Bhowmik A, Seemungal TA, Sapsford RJ, et al. 2000. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax, 55:114-20.
9. Brain JD. 1980. Macrophage damage in relation to the pathogenesis of lung diseases. Environ Health Perspect, 35:21-8.
10. Bucchioni E, Kharitonov SA, Allegra L, et al. 2003. High levels of interleukin-6 in exhaled breath condensate of patients with COPD. Respir Med, 97:1299-302.
11. Chung KF. 2001. Cytokines in chronic obstructive pulmonary disease. Eur Respir J, 18:50s-9s.
12. Churg A, Wang RD, Tai H, et al. 2004. Tumor necrosis factor-α drives 70% of cigarette smoke induced emphysema in the mouse. Am J Respir Crit Care Med, 170:492-8.
13. Cline AM, Radic MZ. 2004. Apoptosis, sub-cellular particles and autoimmunity. Clin Immunol, 112:175-82.
14. Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature, 420:860-7.
15. Crooks SW, Bayley DL, Hill SL, et al. 2000. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J, 15:274-80.
16. Croxford JL, Olson JK, Miller SD. 2002. Epitope spreading and molecular mimicry as triggers of autoimmunity in the Theiler's virus-induced demyelinating disease model of multiple sclerosis. Autoimmunity Rev, 1:251-60.
17. de Godoy I, Donahoe M, Calhoun WJ, et al. 1996. Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med, 153:633-7.
18. Di Francia M, Barbier D, Mege JL, et al. 1994. Tumor necrosis factor-α levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 150:1453-5.
19. Di Stefano A, Capelli A, Lusuardi M, et al. 1998. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med, 158:1277-85.
20. Diaz PT, King MA, Pacht ER, et al. 2000. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med, 132:369-72.
21. + T lymphocytes in experimental lung disease. J Clin Invest, 102:1653-61.
22. Feghali-Bostwick CA, Tsai CG, Valentine VG, et al. 2007. Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J. Immunol, 179:2592-9.
23. Feghali-Bostwick CA, Gadgil AS, Otterbein LE, et al. 2008. Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 177:156-63.
24. Ferrarotti I, Zorzetto M, Beccaria M, et al. 2003. Tumor necrosis factor family genes in a phenotype of COPD associated with emphysema. Eur Respir J, 21:444-9.
25. Finkelstein R, Fraser RS, Ghezzo H, et al. 1995. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med, 152:1666-72.
26. Francus T, Klein RF, Staiano-Coico L, et al. 1988. II. TGP stimulates the proliferation of human T cells and the differentiation of human B cells into Ig secreting cells. J Immunol, 140:1823-9.
27. Fujita M, Shannon JM, Irvin CG, et al. 2001. Overexpression of tumor necrosis factor-α produces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol, 280:L39-L49.
28. Gadgil A, Zhu X, Sciurba FC, Duncan SR. 2006. Altered T-cell phenotypes in chronic obstructive pulmonary disease. Proc Am Thorac Soc, 3:487-8.
29. Gompertz S, O'Brien C, Bayley DL, et al. 2001. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J, 17:1112-9.
30. Grumelli S, Corry DB, Song L, et al. 2004. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med, 1:e8.
31. Henkart P. 1994. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity, 1:343-6.
32. Higham MA, Pride NB, Alikhan A, et al. 2000. Tumor necrosis factor-α gene promoter polymorphism in chronic obstructive pulmonary disease. Eur Respir J, 15:281-4.
33. Hill AT, Campbell EJ, Hill SL, et al. 2000. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med, 109:288-95.
34. Hitomi H, Yoshimoto T, Hayashi N, et al. 2004. IL-18 together with anti-CD3 antibody induces human Th1 cells to produce Th1- and Th2 cytokines and IL-8. Int Immunol, 16:1733-9
35. Hodge G, Nairn J, Holmes M, et al. 2007. Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD. Clin Exp Immunol, 150:22-9.
36. Hodge S, Hodge G, Scicchitano R, et al. 2003. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol, 81:289-96.
37. Hogg JC, Chu F, Utokaparch S, et al. 2004. The nature of small-airway obstrcution in chronic obstructive pulmonary disease. N Engl J Med, 350:2645-53.
38. Houghton AM, Quinterro PA, Perkins DL, et al. 2006. Elastin fragments drive disease progression in a murine model of emphysema. J Clin Invest, 116:753-9,
39. Huang SL, Su CH, Chang SC. 1997. Tumor necrosis factor-α gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med, 156:1436-9.
40. Keatings VM, Collins PD, Scott DM, et al. 1996. Differences in inter leukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med, 153:530-4.
41. Kojima H, Shinohara N, Hanaoka S, et al. 1994. Two distinct pathways of specific killing revealed by perform mutant cytotoxic T-lymphocytes. Immunity, 1: 357-64.
42. Korn S, Wiewrodt R, Walz YC, et al. 2005. Characterization of the interstitial lung and peripheral blood T cell receptor repertoire in cigarette smokers. Am J Respir Cell Mol Biol, 32:142-8.
43. Lee JS, Rosengart MR, Kondragunta V, et al. 2007. Inverse association of plasma IL-13 and inflammatory chemokines with lung function impairment in stable COPD: a cross-sectional cohort study. Respir Res, 8:64.
44. Lee SH, Goswami S, Grudo A, et al. 2007. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med, 13:567-9.
45. Lehmann C, Wilkening A, Leiber D, et al. 2001. Lymphocytes in the bronchoalveolar space reenter the lung tissue by means of the alveolar epithelium, migrate to regional lymph nodes, and subsequently rejoin the systemic immune system. Anat Rec, 264:229-36.
46. Lu H, Ouyang W, Huang C. 2006. Inflammation, a key event in cancer development. Mol Cancer Res, 4:221-33.
47. Lucey EC, Keane J, Kuang PP, et al. 2002. Severity of elastase induced emphysema is decreased in tumor necrosis factor-α and interleukin-1β receptor deficient mice. Lab Investig, 82:79-85.
48. + T cells are required for inflammation and destruction in cigarette smoke-induced emphysema in mice. J Immunol, 178:8090-6.
49. Majo J, Ghezzo H, Cosio MG. 2001. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J, 17:946-53.
50. Majori M, Corradi M, Caminati A, et al. Predominant Th1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease. 1999. J Allergy Clin Immunol, 103:458-62.
51. Mannino DM. 2002. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest, 121:121S-6S.
52. Matsuse T, Hayashi S, Kuwano K, et al. Latent adenoviral infection in the pathogenesis of chronic airways obstruction. 1992. Am Rev Respir Dis, 146:177-84.
53. Monaco C, Andreakos E, Kiriakidis S, et al. 2004. T-cell mediated signaling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. Curr Drug Targets Inflamm Allergy, 3:35-42.
54. Morris A, Sciurba FC, Lebedeva IP, et al. 2004. Association of chronic obstructive pulmonary disease and pneumocystis colonization. Am J Respir Crit Care Med, 170:408-13.
55. Murphy K, Travers P, Walport M. 2007. Janeway's Immunobiology, 7th Edition. Oxford: Garland Science.
56. Norris KA, Morris A, Patil S, Fernandes F. 2006. Pneumocystis colonization, airway inflammation and pulmonary function decline in acquired immunodeficiency syndrome. Immunol Res, 36:175-87.
57. Ogawa E, Elliott WM, Hughes F, et al. 2004. Latent adenoviral infection induces production of growth factors relevant to airway remodeling in COPD. Am J Physiol Lung Cell Mol Physiol, 286:L189-L197.
58. Oldstone MB. 2005. Molecular mimicry, microbial infection and autoimmune disease: evolution of the concept. Curr Top Microbiol Immunol, 296: 1-17.
59. + T lymphocytes with FEV1. Am J Respir Crit Care Med, 155:852-7.
60. Patel IS, Seemungal TA, Wilks M, et al. 2002. Relationship between bacterial colonization and the frequency, character, and severity of COPD exacerbations. Thorax, 57:759-64.
61. Pitsiou G, Kyriazis G, Hatzizisi O, et al. Tumor necrosis factor-α serum levels, weight loss and tissue oxygenation in chronic obstructive pulmonary disease. Respir Med, 96:594-8.
62. Quint JK, Wedzicha JA. 2007. The neutrophil in chronic obstructive pulmonary disease. J Allergy Clin Immunol, 119:1065-71.
63. Reid PT, Sallenave JM. 2003. Cytokines in the pathogenesis of chronic obstructive pulmonary disease. Curr Pharm Des, 9:25-38.
64. Rennard SI, Fogarty C, Kelsen S, et al. 2007. The safety and efficacy of Infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 175:926-34.
65. Retamales I, Elliott WM, Meshi B, et al. 2001. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med, 164:469-73.
66. Rouse BT. 2007. Regulatory T cells in health and disease. J Intern Med, 262:78-95.
67. + lymphocytes in the peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 157:822-6.
68. Sakao S, Tatsumi K, Igari H, et al. 2002. Association of tumor necrosis factor-α gene promoter polymorphism with low attenuation areas on high resolution CT in patients with COPD. Chest, 122:416-20.
69. Samet JM, Tager IB, Speizer FE. 1983. The relationship between respiratory illness in childhood and chronic air-flow obstruction in adulthood. Am Rev Respir Dis, 127:508-23.
70. Schirmer M, Vallejo AN, Weyand CM, et al. 1998. Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+ CD28- T cells from rheumatoid arthritis patients. J Immunol, 161:1018-25.
71. Schleimer RP. 2005. Innate immune responses and chronic obstructive pulmonary disease: "Terminator" or "Terminator 2"? Proc Am Thorac Soc, 2:342-6.
72. Sethi S. 2000. Bacterial infection and the pathogenesis of COPD. Chest, 117:286S-91S.
73. Sethi S, Maloney J, Grove L, et al. 2006. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 173:991-8.
74. Shim JJ, Dabbagh K, Ueki IF, et al. 2001. IL-13 induces mucin production by stimulating epidermal growth factor receptors and by activating neutrophils. Am J Physiol, 280:L134-L140.
75. Sin DD, Man SF. 2008. Impact of cancers and cardiovascular diseases in chronic obstructive pulmonary disease. Curr Opin Pulm Med, 14:115-21.
76. Smyth LJC, Starkey C, Vestbo J, et al. CD4-regulatory cells in COPD patients. Chest, 132:156-63.
77. Soler N, Ewig S, Torres A, et al. 1999. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J, 14:1015-22.
78. Song W, Zhao J, Li Z. 2001. Interleukin-6 in bronchoalveolar lavage fluid from patients with COPD. Chin Med J (Engl), 114:1140-2.
79. Studer SM, George MP, Zhu X, et al. 2008. CD28 downregulation on CD4 T-cells is a marker for graft dysfunction in lung transplant recipients. Am J Respir Crit Care Med (In Press).
80. Sullivan AK, Simonian PL, Falta MT, et al. 2005. Oligoclonal CD4+ T-cells in the lungs of patients with severe emphysema. Am J Respir Crit Care Med, 172:590-6.
81. Tetley TD. 2005. Inflammatory cells and chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy, 4:607-18.
82. + T-lymphocyte subpopulations in chronic obstructive pulmonary disease. Respir Med, 98:57-65.
83. van der Straat BWA, Postma DS, Brandsma CA, et al. 2006. Cigarette smoke-induced emphysema: a role for the B-cell. Am J Respir Crit Care Med, 173:751-8.
84. Vanderlugt CL and Miller SD. 2002. Epitope spreading in immune mediated diseases: implications for immunotherapy. Nat Rev Immunol, 2:85-94.
85. Vandivier RW, Henson PM, Douglas IS. 2006. Burying the dead: the impact of failed apoptotoc cell removal (efferocytosis) on chronic inflammatory lung disease. Chest, 129:1673-82.
86. Wang Z, Zheng T, Zhu Z, et al. 2000. Interferon γ induction of pulmonary emphysema in the adult murine lung. J Exp Med, 192:1587-99.
87. Wilkinson TM, Patel IS, Wilks M, et al. 2003. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 167:1090-5.
88. Yamamoto C, Yoneda T, Yoshikawa M, et al. 1997. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest, 112:505-10.
89. Zheng T, Zhu Z, Wang Z, et al. 2000. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest, 106:1081-93.